Skip to main content

Table 2 Baseline patient demographics: safety population BENEFIT-Korea study

From: Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex: a subanalysis from the BENEFIT-KOREA study

Variable Male (n = 1871) Female (n = 1269) Total (n = 3140)
Age (yr)
  < 50 359 (11.4) 124 (4.0) 483 (15.4)
 50–69 976 (31.1) 508 (16.2) 1484 (47.3)
  ≥ 70 536 (17.1) 637 (20.3) 1173 (37.4)
Height (cm)a 168.7 ± 6.7 154.2 ± 6.1 162.7 ± 9.6
Body weight (kg)b 73.4 ± 12.5 60.8 ± 10.2 68.1 ± 13.2
Waist circumference (cm)c 90.0 ± 9.0 84.4 ± 9.6 87.7 ± 9.6
BMI (kg/m2)d 25.7 ± 3.5 25.5 ± 4.0 25.6 ± 3.8
Cardiocerebrovascular risk factors present 1825 (97.5) 1192 (93.9) 3017 (96.1)
 Male ≥45 yr, female ≥55 yr 1643 (90.0) 1064 (89.3) 2707 (89.7)
 Current smoker 451 (24.7) 21 (1.8) 472 (15.6)
 BMI ≥25 kg/m2, or waist circumference > 90 cm (male) or > 80 cm (female) 673 (36.9) 455 (38.2) 1128 (37.4)
 Dyslipidemia 911 (49.9) 613 (51.4) 1524 (50.5)
 Impaired fasting glucose or impaired glucose tolerance 42 (2.3) 15 (1.3) 57 (1.9)
 Family history of early cardiocerebrovascular disease (male, < 55 yr, female < 65 yr) 84 (4.6) 69 (5.8) 153 (5.1)
 Diabetes mellitus 549 (30.1) 323 (27.1) 872 (28.9)
Medical history present 1667 (89.1) 1131 (89.1) 2798 (89.1)
 Diseases of circulatory system 1234 (74.0) 773 (68.4) 2007 (71.7)
 Endocrine, nutritional and metabolic diseases 1045 (62.7) 713 (63.0) 1758 (62.8)
 Diseases of genitourinary system 276 (16.6) 123 (10.9) 399 (14.3)
 Diseases of digestive system 138 (8.3) 140 (12.4) 278 (9.9)
 Diseases of musculoskeletal system and connective tissue 98 (5.9) 111 (9.8) 209 (7.5)
Use of concomitant treatment with anti-hypertensives with nebivolol 1460 (78.0) 984 (77.5) 2444 (77.8)
 Calcium antagonists 816 (55.9) 512 (52.0) 1328 (54.3)
 Angiotensin II receptor antagonists 724 (49.6) 583 (59.3) 1307 (53.5)
 Diuretics 299 (20.5) 279 (28.4) 578 (23.7)
 ACE inhibitors 183 (12.5) 42 (4.3) 225 (9.2)
 Alpha-blockers 24 (1.6) 9 (0.9) 33 (1.4)
 Not available 10 (0.7) 2 (0.2) 12 (0.5)
  1. Values are presented as number (%) or mean ± standard deviation
  2. P-value (t-test) for the difference between male and female was significant (P < 0.001) for height, weight, and waist circumference
  3. BMI body mass index, ACE angiotensin-converting enzyme
  4. aHeight measurement: male (1217), female (867). b Body weight measurement: male (1212), female (868). c Waist circumference: male (292), female (208). dBMI: male (1174), female (846)